Cargando…

Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer

Modern chemotherapy agents transformed standard care for metastatic colorectal cancer (mCRC) but raised concerns about the financial burden of the disease. We studied comparative effectiveness of treatment plans that involve up to three lines of therapies and impact of treatment sequencing on health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toumazis, Iakovos, Kurt, Murat, Toumazi, Artemis, Karacosta, Loukia G., Kwon, Changhyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124942/ https://www.ncbi.nlm.nih.gov/pubmed/30288431 http://dx.doi.org/10.1177/2381468317729650

Ejemplares similares

From imaging a single cell to implementing precision medicine: an exciting new era
por: Karacosta, Loukia G.
Publicado: (2021)

Phenotypic maps for precision medicine: a promising systems biology tool for assessing therapy response and resistance at a personalized level
por: Bhattacharyya, Sayantan, et al.
Publicado: (2023)

A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker
por: Toumazis, Iakovos, et al.
Publicado: (2021)

Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility
por: Maki, Kristin G., et al.
Publicado: (2022)

Prevalence of Lung Cancer Screening Among Eligible Adults in 4 US States in 2021
por: Maki, Kristin G., et al.
Publicado: (2023)

Two invasions at once: update on the introduction of the invasive species Aedes aegypti and Aedes albopictus in Cyprus – a call for action in Europe
por: Vasquez, Marlen Ines, et al.
Publicado: (2023)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

In-line filtration in very preterm neonates: a randomized controlled trial
por: Virlouvet, Anne-Laure, et al.
Publicado: (2020)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-Line Chemotherapy
por: Bazarbashi, Shouki, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings
por: Toumazis, Iakovos, et al.
Publicado: (2019)

Comparative Effectiveness of Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer
por: Satram-Hoang, Sacha, et al.
Publicado: (2012)

Occurrence and Characteristics of Hospitalizations During First-Line Chemotherapy Among Individuals with Metastatic Colorectal Cancer
por: Fisch, Michael J, et al.
Publicado: (2020)

Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
por: de Takats, P. G., et al.
Publicado: (1994)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
por: Schirripa, Marta, et al.
Publicado: (2018)

No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer
por: Antoun, Sami, et al.
Publicado: (2019)

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
por: Muro, Kei, et al.
Publicado: (2019)

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
por: Klein-Scory, Susanne, et al.
Publicado: (2020)

Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer
por: Saunders, M P, et al.
Publicado: (2003)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study
por: Maddalena, Chiara, et al.
Publicado: (2021)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

Prolonged survival in metastatic colorectal cancer following chemotherapy
por: Paul, Doru, et al.
Publicado: (2014)

Use of perioperative chemotherapy in colorectal cancer metastatic to the liver
por: Symonds, Lynn K, et al.
Publicado: (2019)

Management of chemotherapy dose intensity for metastatic colorectal cancer
por: Chu, Xuelei, et al.
Publicado: (2022)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
por: Pataky, Reka E., et al.
Publicado: (2021)

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study
por: Marschner, Norbert, et al.
Publicado: (2015)

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer
por: Kim, Sejin, et al.
Publicado: (2022)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer
por: Moon, Joon Ho, et al.
Publicado: (2007)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer
por: Zhao, Jing, et al.
Publicado: (2013)

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
por: Schuurhuizen, Claudia SEW, et al.
Publicado: (2018)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon
por: Temraz, Sally, et al.
Publicado: (2022)

Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy
por: Guo, Guifang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7gspvangc8qqbqqnm58cvp63ck